A Study to Test Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Intravenous Doses of Zampilimab in Healthy Participants

Healthy Study Participants Clinical Trial

Official title:

A Randomized, Participant-Blind, Investigator-Blind, Placebo-Controlled Study Evaluating Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Intravenous Doses of Zampilimab in Healthy Participants

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04705350
• Other study ID #: UP0105
• Secondary ID: 2020-004411-26
• Status: Completed
• Phase: Phase 1
• Start date: January 11, 2021
• Est. completion date: July 28, 2021

Study information

• Verified date: July 2022
• Source: UCB Pharma
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics (PK) of zampilimab in healthy study participants.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 16
• Est. completion date: July 28, 2021
• Est. primary completion date: July 28, 2021
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 55 Years

Eligibility

Inclusion Criteria:

• Participant must be 18 to 55 years of age inclusive, at the time of signing the Informed Consent Form (ICF)
• Study participant must be considered reliable and capable of adhering to the protocol, according to the judgment of the Investigator, and is able to communicate satisfactorily with the Investigator and comply with all clinical study requirements
• Study participant has adequate peripheral venous access
• Study participant has clinical laboratory test results within the reference ranges of the testing laboratory. Study participants with test results that are outside the specified ranges and that are deemed as clinically nonsignificant will be allowed at the discretion of the Investigator
• Study participant is of normal weight as determined by a body mass index between 18 and 32 kg/m^2, inclusive, with a body weight of at least 50 kg (male) or 45 kg (female) and no greater than 100 kg
• Study participants may be male or female
• Male participants must agree to use contraception during treatment period and for 5 months; female participants of childbearing potential must be not pregnant or breastfeeding and agree to use contraception during the treatment period and for 5 months

Exclusion Criteria:

• Study participant has any medical (acute or chronic) or psychiatric condition that, in the opinion of the Investigator, could jeopardize or would compromise the study participant's ability to participate in this study
• History or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrinological, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; constituting a risk when taking the IMP; or interfering with the interpretation of data
• Study participant has a known hypersensitivity to any components of the investigational medicinal product (IMP) as stated in this protocol or participant has a history of moderate to severe allergic reaction to medication(s), including biologics
• Study participant has any clinically relevant abnormal findings in physical examination, laboratory tests, vital signs, or electrocardiogram (ECG), which, in the opinion of the Investigator, may place the participant at risk because of participation in the study
• Study participant has had major surgery (including joint surgery) within 6 months prior to the Screening Period, or has planned surgery within 6 months after IMP
• Study participant has current diagnosis or history of wound healing complications
• Study participant has a history of alcohol and/or drug abuse up to 6 months before the Screening Period
• Study participant has active neoplastic disease or history of neoplastic disease within 5 years of the Screening Period
• Study participant has an active infection during the Screening Period
• Study participant has clinical signs and symptoms consistent with coronavirus disease (COVID-19) or had a positive severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) test result within the last 4 weeks prior to the Screening Period or on admission
• Study participant has had a severe course of COVID-19 that required hospitalization
• Study participant has received any prescription or nonprescription medicines, including over the counter (OTC) remedies or herbal and dietary supplements, within 14 days or 5 half-lives of the respective drug, whichever is longer, other than the occasional use of analgesics, such as paracetamol (acetaminophen) or ibuprofen, oral contraceptives, or inhaled corticosteroids for seasonal rhinitis
• Study participant has received treatment with biologic agents (such as monoclonal antibodies (mAbs) including marketed drugs) within 3 months or 5 half-lives (whichever is longer) prior to dosing
• Study participant has received a vaccination within 8 weeks prior to Day 1; or intends to have a vaccination during the course of the study
• Study participant has participated in another study of a IMP (and/or an investigational device) within the previous 3 months or 5 half-lives prior to the Screening Period, whichever is longer, or is currently participating in another study of a IMP (and/or an investigational device)
• Study participant has positive serology test for hepatitis B surface antigen, hepatitis B core antibodies (both immunoglobulin G (IgG) and IgM), hepatitis C virus antibodies, or antibodies to human immunodeficiency virus type 1 and/or type 2 during the Screening Period

Related Conditions & MeSH terms

• Healthy Study Participants

Intervention

Drug:
• Zampilimab
Participants will receive a single intravenous dose of zampilimab at a pre-specified time point.
• Placebo
Participants will receive matching placebo at a pre-specified time point to maintain the blinding.

Locations

Country	Name	City	State
United Kingdom	Up0105 001	London

Sponsors (1)

Lead Sponsor	Collaborator
UCB Biopharma SRL

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidents of treatment-emergent adverse events (TEAEs) through the Safety Follow-up (SFU) Visit	A treatment-emergent adverse event (TEAE) is defined as any event not present prior to the administration of investigational medicinal product (IMP) or any unresolved event already present before administration of IMP that worsens in intensity following exposure to the treatment.	From Day 1 (Start of Treatment Period) to the end of Safety Follow-up (up to 120 days)
Primary	Maximum intensity of treatment-emergent adverse events (TEAEs) through the Safety Follow-up (SFU) Visit	Maximum intensity across all incidents of each TEAE for each study participant	From Day 1 (Start of Treatment Period) to the end of Safety Follow-up (up to 120 days)
Secondary	Maximum zampilimab serum concentration (Cmax)	Cmax: Maximum observed zampilimab serum concentration	From Day 1 (Start of Treatment Period) to the end of Safety Follow-up (up to 120 days)
Secondary	Time to maximum zampilimab serum concentration (tmax)	tmax: Time to maximum observed zampilimab serum concentration	From Day 1 (Start of Treatment Period) to the end of Safety Follow-up (up to 120 days)
Secondary	Area under the zampilimab serum concentration-time curve from time zero to last quantifiable concentration (AUC0-t)	AUC0-t: Area under the zampilimab serum concentration-time curve from time zero (Day 1) to the last quantifiable concentration	From Day 1 (Start of Treatment Period) at predefined time points to the last quantifiable concentration (up to 120 days)
Secondary	Area under the zampilimab serum concentration-time curve from time zero to infinity (AUC)	AUC: Area under the zampilimab serum concentration-time curve from time 0 (Day 1) to infinity	Day 1 (Start of Treatment Period) at predefined time points (up to 120 days)
Secondary	Clearance (CL) of zampilimab in serum	CL: volume of serum that is cleared from zampilimab per unit of time	From Day 1 (Start of Treatment Period) to the end of Safety Follow-up (up to 120 days)
Secondary	Apparent volume of distribution during terminal phase (Vz) of zampilimab	Vz: apparent volume of distribution during terminal phase	From Day 1 (Start of Treatment Period) to the end of Safety Follow-up (up to 120 days)
Secondary	Apparent terminal half-life (t1/2) of zampilimab	t1/2: terminal zampilimab serum half-life	From Day 1 (Start of Treatment Period) to the end of Safety Follow-up (up to 120 days)